BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22555040)

  • 1. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
    Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
    Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer.
    Reis ST; Pontes-Junior J; Antunes AA; de Sousa-Canavez JM; Dall'Oglio MF; Passerotti CC; Abe DK; Crippa A; da Cruz JA; Timoszczuk LM; Srougi M; Leite KR
    Int J Biol Markers; 2011; 26(4):255-61. PubMed ID: 22139647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
    Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
    Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer.
    Reis ST; Leite KR; Piovesan LF; Pontes-Junior J; Viana NI; Abe DK; Crippa A; Moura CM; Adonias SP; Srougi M; Dall'Oglio MF
    BMC Urol; 2012 Jun; 12():18. PubMed ID: 22695075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
    Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
    Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
    Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in mRNA and protein levels of metalloproteinases-2, -9, and -14 and tissue inhibitor of metalloproteinase-2 responses to traumatic skeletal muscle injury.
    Barnes BR; Szelenyi ER; Warren GL; Urso ML
    Am J Physiol Cell Physiol; 2009 Dec; 297(6):C1501-8. PubMed ID: 19794148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
    Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
    Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression.
    Kogianni G; Walker MM; Waxman J; Sturge J
    Eur J Cancer; 2009 Mar; 45(4):685-93. PubMed ID: 19112015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort.
    Srivastava P; Kapoor R; Mittal RD
    Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
    Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
    Hum Pathol; 2008 May; 39(5):731-9. PubMed ID: 18329693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer.
    Reis ST; Pontes-Júnior J; Antunes AA; Sousa-Canavez JM; Abe DK; Cruz JA; Dall'oglio MF; Crippa A; Passerotti CC; Ribeiro-Filho LA; Viana NI; Srougi M; Leite KR
    Clinics (Sao Paulo); 2011; 66(7):1143-7. PubMed ID: 21876965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Matrix Metalloproteases by Artificial Intelligence Techniques in Negative Biopsies as New Diagnostic Strategy in Prostate Cancer.
    Eiro N; Medina A; Gonzalez LO; Fraile M; Palacios A; Escaf S; Fernández-Gómez JM; Vizoso FJ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.
    Chernov AV; Sounni NE; Remacle AG; Strongin AY
    J Biol Chem; 2009 May; 284(19):12727-34. PubMed ID: 19286653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.